Changes in coagulation and fibrinogenolysis (factor VII clotting activity and type 1 plasminogen activator inhibitor) in patients with obstructive sleep apnea syndrome following nasal continuous positive airway pressure therapy.

因子VII染色活动（FVIIc）是一个独立的风险因素，在急性呼吸道综合征（OSAS）前对15名患者进行了观察，在急性呼吸道和急性呼吸道指数（AHI） 62±4 （平均±SEM）和之后（AHI 3±1） nasal持续阳性气道压力（nCPAP）治疗，在1个月后治疗，在6个月后治疗。FVIIc水平在nCPAP治疗后进行了研究。After 6 months of nCPAP治疗， FVIIc levels had decreased significantly （before 141± 12% vs. after 6 months 111± 6%;p<0.01）。此声明在FVIIc后长期nCPAP治疗可以提高OSAS患者的死亡率。Visceral肥胖累积（VFA）是一个更好的冠状心脏病预测，和亚切肥胖累积（SFA）是由计算断层扫描之前和之后nCPAP治疗在22个OSAS患者（平均AHI>50）。其他21个OSAS患者的血清瘦素水平在nCPAP之前和之后的3-4天内被测量到nCPAP影响的脂肪分布中的机制。VFA and SFA decreased significantly after 6 months of nCPAP treatment （VFA：from 236 ±16 to 182± 14 cmイルD12イルD1， p= 0. 0003;SFA： from 215±21 to 189±18 cmイルD12イルD1， p= 0. 003）。在体重减少（BWR）组（n=9， p<0.01）和无BWR组（n=13， p<0.03）中明显减少VFA。仅在BWR组中更改了SFA（p<0.01）。Leptin水平在nCPAP 3-4天内显著地跟随（p<0.01），但当身体重量、快速胰岛素或皮质激素水平没有显著地改变。通过nCPAP纠正睡眠紊乱的呼吸可能会使用来减少OSAS患者中的VFA。OSAS可能对血清素水平有重大影响。

Factor VII clotting activity (FVIIc) which is an independent risk factor for ischemic heart disease, was investigated prospectively in 15 patients with obstructive sleep apnea syndrome (OSAS) before apnea and hypopnea index (AHI) 62±4 (mean±SEM) and after (AHI 3±1) nasal continuous positive airway pressure (nCPAP) treatment for immediate relief, at 1 month after treatment and at over 6 months. FVIIc levels gradually decreased after nCPAP treatment. After 6 months of nCPAP treatment, FVIIc levels had decreased significantly (before 141±12% vs. after 6 months 111±6%;p<0.01). This decrease in FVIIc after long-term nCPAP treatment could improve mortality in OSAS patients.Visceral fat accumulation (VFA) which is a better predictor of coronary heart disease, and subcutaneous fat accumulation (SFA) were assessed by computed tomography before and after nCPAP treatment in 22 OSAS patients (mean AHI>50). Serum leptin levels of another 21 OSAS patients were measured before and after 3-4 days of nCPAP to gain insight into the mechanism by which nCPAP affects fat distribution. VFA and SFA decreased significantly after 6 months of nCPAP treatment (VFA: from236±16 to 182±14cmィイD12ィエD1, p=0.0003;SFA: from 215±21 to 189±18 cmィイD12ィエD1, p=0.003). The VFA decreased significantly in the body weight reduction (BWR) group (n=9, p<0.01) and No-BWR group (n=13, p<0.03). In contrast, SFA changed significantly in the BWR group only (p<0.01). Leptin levels decreased significantly following 3-4 days of nCPAP (p<0.01), while body weight, fasting insulin or cortisol levels did not change significantly. Correcting of sleep disordered breathing by nCPAP may be used to reduce VFA in OSAS patients. OSAS may have significant effects on the serumleptin levels.